Peptides from the calcitonin genes: molecular genetics, structure and function.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
M Zaidi
Publications and source records attributed to M Zaidi.
A highly specific and sensitive enzyme-immunometric assay for calcitonin gene-related peptide based on enzyme amplification.
Calcitonin gene-related peptide (CGRP) is an important member of the peptide family encoded by the calcitonin gene. It has been found to be a potent vasodilator in man and a major circulating gene product (Girgis et al., 1985). The present study reports the development of a sensitive and rapid two-site immunoassay for CGRP based on enzyme amplification (Self, 1985). The assay has been easy to construct, taking advantage of available antisera raised for other purposes. Nevertheless it has been found to be clearly superior to our previous radioimmunoassay in terms of sensitivity, specificity, speed and convenience.
Animals↗
Evidence for release of calcitonin gene-related peptide and neurokinin A from sensory nerve endings in vivo.
Sensitive radioimmunoassays for calcitonin gene-related peptide and the tachykinin, neurokinin A, have been used to show that acute administration of the sensory neurotoxin capsaicin (10 mg/kg i.p.) to normal adult rats, causes a substantial release of calcitonin gene-related peptide immunoreactivity (15-fold increase) and neurokinin A immunoreactivity (4- to 5-fold increase) into the plasma. Neonatal administration of capsaicin (50 mg/kg s.c.) produced a long term deficit in the lumbar dorsal root ganglia content of calcitonin gene-related peptide (76% depletion), and neurokinin A immunoreactivity (86% depletion) in rats killed 6 weeks after administration. Acute capsaicin treatment of neonatally capsaicin-treated rats revealed that these animals still showed a capsaicin-evoked release of calcitonin gene-related peptide and neurokinin A immunoreactivity into the plasma. The increase in plasma content was, however, substantially less than that seen in normal (vehicle-treated) rats and was proportional to the initial basal plasma level of the respective peptides. Immunohistochemical staining using an anti-calcitonin gene-related peptide antiserum revealed that, despite the neonatal capsaicin treatment and loss of dorsal root ganglia content, the lumbar dorsal horn had a near normal pattern of calcitonin gene-related peptide immunoreactivity. This observation was supported by radioimmunoassays carried out on lumbar dorsal horn samples obtained from the same rats, which showed no significant decrease in calcitonin gene-related peptide immunoreactivity, whilst the dorsal horn content of neurokinin A was some 70% below control values.(ABSTRACT TRUNCATED AT 250 WORDS)
Animals↗
Effects of peptides from the calcitonin genes on bone and bone cells.
The calcitonin-calcitonin gene-related peptide (CGRP) gene complex encodes a family of novel peptides--calcitonin, CGRP and katacalcin. Whereas calcitonin is a circulating hormone involved in skeletal maintenance, the physiological function of CGRP still remains unclear. In the present study we have compared the biological activity of CGRP with that of calcitonin using three experimental systems. We have demonstrated that both peptides inhibit bone resorption by active rat osteoclasts and thus lower plasma calcium when injected into young rats. In both respects the CGRP homologues (rat, human alpha and human beta) were found to be 100- to 1000-fold less potent than human calcitonin. The effects of the CGRP peptides and calcitonin were only additive. Human CGRP (alpha) also caused a marked dose-dependent elevation of bone cyclic AMP levels in mice, somewhat like calcitonin. Though from our studies it would seem reasonably clear that CGRP is weakly agonistic for the calcitonin receptor on the osteoclast to produce effects on bone resorption and plasma calcium, it is still unclear whether the elevation of bone cyclic AMP simply represents an osteoclastic effect or an additional, more important, effect on osteoblasts. It is highly unlikely that CGRP may exert systemic effects on bone. Nevertheless, the peptide may be an important local regulator of bone cell function.
Animals↗
Development and performance of a highly sensitive carboxyl-terminal-specific radioimmunoassay of calcitonin gene-related peptide.
The calcitonin genes encode a small family of peptides: the circulating hormone calcitonin; its flanking peptide, katacalcin; and a third novel peptide, calcitonin gene-related peptide (CGRP). CGRP is a potent vasodilator and a major circulating product from the calcitonin genes; it may be a physiologically important regulator of blood flow in humans. High concentrations of circulating CGRP are found in medullary thyroid carcinoma. We report the development and validation of a highly sensitive (detection limit 500 amol per tube) radioimmunoassay of CGRP involving a high-affinity antibody directed against the carboxyl terminus of the molecule and a highly pure tracer. The assay is precise, robust, and reproducible, and is therefore a potentially useful analytical method for studying the normal and abnormal physiology of this peptide.
Antibody Specificity↗
Transient appearance of calcitonin gene-related peptide-like immunoreactive fibers in the developing cerebellum of the rat.
A plexus of calcitonin gene-related peptide (CGRP)-containing fibers were transiently found in the developing cerebellum of the rat by means of the indirect immunofluorescent method. CGRP-like immunoreactive fibers appeared in the cerebellum by embryonic day 22. Immunoreactive fibers rapidly increased and these made a dense plexus in the Purkinje cell layer by postnatal day 2. However, only a few if any immunoreactive fibers were seen in the Purkinje cell layer or molecular layer of adult rats.
Animals↗
Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study.
Besides the calcitonin (CT) precursor, the calcitonin gene also encodes another peptide--calcitonin gene-related peptide (CGRP). We have previously reported that CGRP lowers plasma calcium in the rat. In the present study we have evaluated the effect of CGRP on resorption of bone by isolated rat osteoclasts and have compared these effects to those produced by calcitonins from three species (salmon, pig, and human calcitonins). There was a significant inhibition of bone resorption with rat calcitonin gene-related peptide (rCGRP) at a 1000-fold higher dose than that used for human CT. This effect well explains the CT-like effect of CGRP seen in the in vivo rat CT bioassay. Our results suggest that though CGRP may not be involved in the hormonal control of plasma calcium, the peptide may be an important local regulator of bone cell function.
Animals↗
Biology of peptides from the calcitonin genes.
Despite being products from the same gene, there is clearly a marked divergence in the distribution and physiological role of calcitonin and CGRP. Whereas calcitonin is predominantly distributed in the thyroid, CGRP is abundant in the nervous system throughout the body. Though the peptides have only weak structural homologies, a generally similar conformation enables them to interact at each other's receptors. Hence the pharmacological effects of the peptides faintly resemble one another. Calcitonin receptors are mainly found on osteoclasts and at certain sites in the nervous system. CGRP binding sites are abundant in the cerebellum and blood vessels. Calcitonin is a circulating hormone controlling osteoclastic activity. CGRP acts as a neurotransmitter or neuromodulator centrally, and released from perivascular nerve terminals, it modulates arteriolar tone. Released from motoneurones, CGRP may also play a trophic role regulating the muscle acetylcholine receptor state. The next decade should establish the physiological role of CGRP and the regulation of the expression of the calcitonin/CGRP gene complex.
Animals↗
A direct action of human calcitonin gene-related peptide on isolated osteoclasts.
The calcitonin gene encodes a small family of peptides: calcitonin, calcitonin gene-related peptide (CGRP) and katacalcin. Whereas calcitonin is concerned with skeletal maintenance, the function, if any, of katacalcin is still unknown. In the present study we have assessed resorption of human cortical bone substrate by isolated rat osteoclasts and have shown that CGRP acts directly on the osteoclast to inhibit bone resorption. The three CGRP peptides (rat, human(alpha) and human(beta) caused an almost equivalent decrease in osteoclastic bone resorption and were approximately 1000-fold less potent than human calcitonin in this respect. The responses of human calcitonin and human CGRP(alpha) were additive. Furthermore, prior treatment with trypsin to destroy receptors abolished the responsiveness of osteoclasts to CGRP and calcitonin. The carboxyl- and amino-terminal fragments of CGRP were found not to inhibit bone resorption, suggesting that the whole molecule of CGRP is necessary for biological activity. We have therefore suggested that the calcitonin-like effects of CGRP, seen both in vivo in the rat bioassay and in vitro in organ cultures, are due to the direct action of CGRP on the osteoclast, probably mediated through the calcitonin receptor. Though it is unlikely that CGRP is involved in the regulation of plasma calcium, the peptide may be an important local regulator of bone cell function.
Animals↗
Calcitonin and the peptides from the calcitonin gene.
The alpha-calcitonin gene encodes a small family of peptides: calcitonin, katacalcin, and calcitonin gene-related peptide (CGRP). Calcitonin and katacalcin are produced from one precursor and CGRP from another. Calcitonin and katacalcin come mainly from the thyroid, while CGRP is present in both the thyroid and the central nervous system. Calcitonin is concerned with skeletal integrity, while the function of katacalcin, if any, is unknown. The secretion of calcitonin is, in part, estrogen dependent, and it appears likely that a postmenopausal decline in calcitonin secretion is a factor in the development of postmenopausal osteoporosis. It is possible that calcitonin may prove useful in the prevention and perhaps the treatment of this condition. CGRP, conversely, is one of the most potent vasodilators known and probably plays an important physiologic role in the control of vessel tone and blood flow. CGRP may also have a role as neurotransmitter or neuromodulator.
Amino Acid Sequence↗
The origin of circulating calcitonin gene-related peptide in the rat.
It is known that in addition to the calcitonin precursor the calcitonin gene also encodes a novel peptide, calcitonin gene-related peptide (CGRP). This potent vasodilator has been found in the circulation of man. This present study demonstrates that CGRP is also found in the circulation of the rat and that plasma CGRP comes from two different sources: the thyroid, a major source in old rats, and the perivascular nerves probably at all ages.
Adrenal Glands↗
Circulating CGRP comes from the perivascular nerves.
Explore the source record for details and available documents.
Animals↗
Role of the endothelial cell in osteoclast control: new perspectives.
The osteoclast is of central importance in the process of bone remodeling. Its function is regulated by hormones and locally produced factors. Endothelial cells occur in close proximity to the osteoclast. Some endothelial cell-derived products, including endothelins, nitric oxide, and reactive oxygen species, have been recently implicated as modulators of osteoclast function. Endothelins inhibit bone resorption and osteoclast margin ruffling (quiescence or Q effect) at concentrations similar to those effective for their primary vasoconstrictive action. Contrary to expectations, however, it has been shown that endothelin action on the osteoclast is not mediated through an elevation of cytosolic Ca2+. Nitric oxide (NO) produces marked cell retraction (retraction or R effect), but its detailed mode of action is unknown. However, it is clear that the effects of this autocoid are not due to enhanced cyclic guanosine monophosphate (cGMP) production, a transduction system commonly used by NO. Finally, the reactive oxygen species H2O2 has been shown recently to enhance osteoclastic activity. Thus, the reported effects of the endothelial cell-derived products on the osteoclast are generally consistent with a regulatory role for endothelial cells in osteoclast control and suggest the existence of unique activation pathways, well worth exploring further. Unravelling the responsible mechanisms may also help understand the pathophysiology of a range of bone and joint diseases. For example, in rheumatoid arthritis, there is increased H2O2 production from activated neutrophils, and bone resorption is a major pathophysiological feature.
Bone Remodeling↗
A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion.
The in-vitro activity of fluconazole against 46,831 yeast isolates collected over a two-year period from 57 laboratories in 33 countries worldwide was assessed using a disc diffusion method. Candida albicans was the organism isolated most frequently, accounting for 68.6% of the total number of isolates. C. glabrata, C. tropicalis, C parapsilosis and C. krusei and Cryptococcus neoformans represented 9.9, 4.7, 4.3, 1.9, and 1.4% of isolates respectively during the 2 year period and rates varied markedly between countries. In 1999 data blood isolates represented 4.9% of all isolates and intensive care unit isolates represented 9.9%. In both the 1998 and 1999 data, 99% of C. albicans were fully susceptible (S) to fluconazole, and 95.6% of all species of yeasts tested were S or susceptible-dose dependent (S-DD) to fluconazole. No emerging trends of resistance were noted with any of the Candida spp. tested as 96% of all isolates retained susceptibility (S or S-DD) to this agent.
Antifungal Agents↗
Novel mechanisms of calcium handling by the osteoclast: A review-hypothesis.
The osteoclast is a cell that is unique in its ability to resorb bone and, in doing so, becomes exposed to unusually high millimolar Ca2+ concentrations. It is generally accepted that, during resorption, osteoclasts can "sense" changes in their ambient Ca2+ concentration. This triggers a sharp cytosolic Ca2+ increase through both Ca2+ release and Ca2+ influx. The change in cytosolic Ca2+ is transduced finally into inhibition of bone resorption. It has been shown that a type 2 ryanodine receptor isoform, expressed uniquely in the plasma membrane, functions as a Ca2+ influx channel and possibly as a Ca2+ sensor. Ryanodine receptors are ordinarily Ca2+ release channels that have a microsomal membrane location in a wide variety of eukaryotic cells, including the osteoclasts. However, only recently has it become obvious that ryanodine receptors are also expressed in osteoclast nuclear membranes, at which site they probably gate nucleoplasmic Ca2+ influx. Nucleoplasmic Ca2+ in turn regulates key nuclear processes, including gene expression and apoptosis. Here, we review the potential mechanisms underlying the recognition, movement, and effects of Ca2+ in the osteoclast. We will also speculate on the general biological significance of the unique processes used by the osteoclast to handle high Ca2+ loads during bone resorption.
Animals↗